fda ban on semaglutide The FDA's Decision to Compounds: What You Need to Know FDA cracking down on Ozempic
Description
MedTech stocks continue to feel pressure from glucagon-like peptide-1 (GLP-1) drugs for obesity, based primarily on speculation, and despite strong third-quarter performances from many firms in this sector

But there also have been troubling side effects reported.

State-specific notes: Note to Washington State providers: For commercial plans, your effective date for changes described in this article will be communicated to you following regulatory review

Roche presented early-stage data on its obesity injection and pill at EASD

In a development that could reshape diabetes care in Canada, the path has been cleared for generic versions of Ozempic and Wegovy to enter the Canadian market in 2026

Clinical studies have shown that continuous use of Rybelsus can lead to significant and sustained weight reduction
